Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 484 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

NCT01206322
Conditions
Type 2 Diabetes Mellitus
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Completed Phase 4 Interventional Results available

Botulinum Toxin in Raynaud's Phenomenon

NCT05125029
Conditions
Raynaud Phenomenon
Interventions
Botulinum toxin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Conditions
Pain
Interventions
Acetaminophen, Bupivacain, Saline
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Acute Blood Loss Anemia, Osteoarthritis, Hip
Interventions
Tranexamic acid, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Detroit, Michigan
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
Conditions
Hepatitis b Virus, Hepatitis B
Interventions
HepB mAb19, Sterile Saline
Biological · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New York, New York
Conditions
Atrial Fibrillation
Interventions
Stellate ganglion block, Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obesity, Overweight or Obesity
Interventions
MET097, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Hollywood, Florida • Tampa, Florida • Atlanta, Georgia + 2 more
Completed Phase 2Phase 3 Interventional Results available

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

NCT04545060
Conditions
Covid19
Interventions
VIR-7831 (sotrovimab), Placebo
Biological · Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
63
States / cities
Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more
Conditions
Spinal Deformity, Degenerative Lumbar Spinal Stenosis, Blood Loss, Surgical
Interventions
Tranexamic Acid 100 MG/ML, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Lung Transplant
Interventions
Tocilizumab, Placebo for Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

NCT00485134
Conditions
Shigellosis
Interventions
240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Ileostomy - Stoma
Interventions
Transversus abdominis plane block
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
SARS-CoV-2
Interventions
mRNA-1273, mRNA-1283, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
150
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

NCT06967181
Conditions
Mumps
Interventions
CVM150, CVM26, Placebo
Biological · Other
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 29 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • North Charleston, South Carolina
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Sodium thiosulfate, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Huntsville, Alabama • Fort Wayne, Indiana • Bethlehem, Pennsylvania
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota
Conditions
Alzheimer Disease
Interventions
Sargramostim, Saline - placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more